Neurology coverage on this site has expanded rapidly as GLP-1 secondary indications keep appearing. AAN 2026 produced multiple readouts covered here: GLP-1 in chronic migraine (10% reduction in ED visits, 14% in hospitalizations vs topiramate), GLP-1 in dementia incidence (20–35% reduction across 2+ million diabetics), and the broader living systematic review of GLP-1 across Alzheimer's, Parkinson's, multiple sclerosis, and stroke.
Other neurology threads: Sanofi's Tzield in T1D-related autoimmunity, Briacell's Bria-IMT in HER2 breast cancer brain metastases, Fedora's lactivicin work on CNS-tropic gram-negatives, and academic programs on neuropeptides and ion-channel-targeted peptides.
Stories here cover the AAN data, registry analyses, and the peptide-neurology pipeline. See #cgrp, #alzheimers, and #parkinsons for narrower threads.
A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.